Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

 Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

Shots:

  • The P-II study involves assessing of LNP023 in PNH patients with active hemolysis despite treatment with eculizumab
  • Results: improvements in hematological response and biomarkers of disease activity; 70% discontinued eculizumab and remained on LNP023 as monothx., retaining Hb levels with no changes in biomarkers of disease activity and with no signs or symptoms of breakthrough hemolysis
  • LNP023 is a potent and highly selective factor B inhibitor of the alternative complement pathway, currently in development for multiple renal conditions with complement system involvement. Additionally, the company is conducting an ongoing P-II study to assess LNP023 as monothx. for anti-C5 naïve PNH patients, with plans to initiate P-III study in late 2020

Click here to­ read full press release/ article | Ref: Novartis | Image: OIS

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post